One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Axsome Therapeutics logo
Axsome Therapeutics AXSM
$ 133.97 -1.02%
report update icon

Quarterly report 2026-Q3
added 11-02-2026

Axsome Therapeutics Financial Statements 2025-2011 | AXSM

Annual Financial Statements Axsome Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

8.67 B 6.16 B 3.59 B 3.21 B 1.03 B 2.54 B 3.01 B 224 M 63.7 M 90 M 93.5 M - - - -

Shares

49.7 M 47.9 M 45.4 M 40.7 M 37.6 M 37.4 M 34 M 26.9 M 22.8 M 19.2 M 11.9 M - - - -

Historical Prices

174 129 79 79 27.4 68.1 86.8 8.39 2.8 4.9 7.83 - - - -

Net Income

-183 M -287 M -239 M -187 M -130 M -103 M -68.3 M -31 M -28.9 M -27.2 M -10.6 M -6 M -2.17 M - -

Revenue

638 M 386 M 271 M 50 M - - - - - - - - - - -

Cost of Revenue

47.5 M 33.3 M 26.1 M 5.2 M - - - - - - - - - - -

Gross Profit

591 M 352 M 245 M 44.8 M - - - - - - - - - - -

Operating Income

-167 M -281 M -232 M -180 M -125 M -99.1 M -67.2 M -32.8 M -27.2 M -27.5 M -9.2 M -5.67 M - - -

Interest Expense

-15.9 M -21.6 M -20 M -9.66 M - - - - - - - - - - -

EBITDA

-166 M -280 M -231 M -180 M -125 M -99 M -67.1 M -32.6 M -26.9 M -27 M -6.91 M -2.74 M -1.84 M - -

Operating Expenses

758 M 633 M 476 M 225 M 125 M 99.1 M 67.1 M 32.6 M 27 M 27.1 M - - - - -

General and Administrative Expenses

63.3 M 54.2 M 37.4 M 25.5 M 66.6 M 28.9 M 13.6 M 9.35 M 7.21 M 6.34 M 2.42 M 1.39 M 304 K - -

All numbers in USD currency

Quarterly Income Statement Axsome Therapeutics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

52.4 M 51.8 M 51.2 M 298 K 50 M 49.4 M 48.9 M 211 K 48.1 M 47.6 M 47.4 M 642 K 47.1 M 43.7 M 43.5 M 941 K 41.7 M 39.1 M 38.3 M 49.2 M 37.7 M 37.6 M 37.4 M 48.4 M 37.3 M 37.1 M 37.1 M 249 K 34.4 M 33.8 M 33.1 M 1.01 M 26.3 M 25.8 M 25.5 M 494 K 23.6 M 23.6 M 19.5 M 1.11 K 19.1 M 19.1 M 19.1 M 19.1 M 11.1 M 11.1 M 11.1 M - - - - - - - - - - - - - - - -

Net Income

-12.9 M -51.3 M -64.5 M -28.6 M -47.2 M -48 M -59.4 M -74.9 M -64.6 M -79.3 M -68.4 M -98.7 M -62.2 M -67.2 M -11.2 M -61.2 M -44.8 M -41.4 M -39.6 M -34 M -34.9 M -32.3 M -29.3 M -29.2 M -22.9 M -18.3 M -32.5 M -24.8 M -19.1 M -13.8 M -10.6 M -9.6 M -8.28 M -8.28 M -4.81 M -7.43 M -6.43 M -7.08 M -8 M -7.33 M -7.19 M -6.81 M -5.87 M -3.36 M -4.58 M -2.13 M -2.14 M - - - - - - - - - - - - - - - -

Revenue

260 M 218 M 191 M 196 M 171 M 150 M 121 M 119 M 105 M 87.2 M 75 M 71.5 M 57.8 M 46.7 M 94.6 M 24.4 M 16.8 M 8.82 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

17.8 M 13.6 M 14.7 M 12.3 M 11.9 M 13.4 M 9.79 M 10.5 M 8.44 M 8.06 M 6.3 M 7.38 M 6.53 M 4.6 M 7.56 M 2.29 M 1.92 M 983 K - - - 1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

242 M 205 M 176 M 184 M 159 M 137 M 112 M 108 M 96.3 M 79.1 M 68.7 M 64.2 M 51.3 M 42.1 M 87 M 22.1 M 14.9 M 7.84 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-11.1 M -49.6 M -63.4 M -27 M -46.1 M -36.7 M -57 M -72.6 M -62.6 M -78 M -67.3 M -98.3 M -62.1 M -65.1 M -6.37 M -59.9 M -42.4 M -39.2 M -38.3 M -32.6 M -33.4 M -30.8 M -27.8 M -27.7 M -21.1 M -17.8 M -32.5 M -24.4 M -18.9 M -13.4 M -10.4 M 9.45 M -8.24 M -7.99 M -7.16 M 6.44 M 6.3 M 6.75 M 7.67 M 7.63 M 7.21 M 6.83 M 5.88 M 3.15 M 2.02 M 2.08 M 1.93 M - - - - - - - - - - - - - - - -

Interest Expense

-3.42 M -3.2 M 3.09 M -3.21 M -3.38 M -4.09 M 5.26 M -5.43 M -5.67 M -5.08 M -5.41 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-9.46 M -48.1 M -61.8 M -25.4 M -44.5 M -35.1 M -55.4 M -71 M -61 M -76.5 M -65.7 M -96.7 M -60.5 M -63.5 M -4.8 M -58.3 M -40.8 M -38.3 M -38.3 M -32.6 M -33.4 M -30.8 M -27.8 M -27.7 M -21.1 M -17.8 M -32.5 M -24.4 M -18.9 M -13.4 M -10.4 M 9.46 M -8.23 M -7.98 M -7.15 M 6.46 M 6.31 M 6.76 M 7.68 M 7.64 M 7.21 M 6.83 M 5.88 M 3.15 M 2.03 M 2.09 M 1.93 M - - - - - - - - - - - - - - - -

Operating Expenses

253 M 254 M 240 M 211 M 205 M 173 M 169 M 181 M 159 M 157 M 136 M 162 M 113 M 107 M 93.4 M 82 M 57.3 M 47 M 38.3 M 32.6 M 33.4 M 30.8 M 27.8 M 27.7 M 21.1 M 17.8 M 32.5 M 24.4 M 18.9 M 13.4 M 10.4 M 9.45 M 8.24 M 7.99 M 7.16 M 6.44 M 6.3 M 6.75 M 7.67 M 7.63 M 7.21 M 6.83 M 5.88 M - 2.02 M 2.08 M 1.93 M - - - - - - - - - - - - - - - -

General and Administrative Expenses

203 M 208 M 185 M 169 M 150 M 130 M 121 M 113 M 95.6 M 104 M 99 M 86.8 M 83.2 M 78.9 M 74.2 M 61.5 M 40.9 M 31.2 M 25.7 M 18.8 M 20.2 M 16.3 M 11.2 M 10.4 M 6.33 M 7.24 M 4.97 M 5.22 M 3.11 M 2.45 M 2.82 M 2.3 M 2.2 M 2.44 M 2.41 M 1.95 M 1.83 M 1.74 M 1.69 M 1.82 M 1.64 M 1.53 M 1.36 M - 499 K 456 K 517 K - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Axsome Therapeutics AXSM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Axsome Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.09 -19.26 % $ 34 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 300.63 0.68 % $ 23.5 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 4.08 0.12 % $ 1.25 B usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
- - $ 1.62 B israelIsrael
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
- 7.4 % $ 6.29 M usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
- - $ 26.6 B irlandaIrlanda
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.48 -3.27 % $ 2.44 M israelIsrael
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 119.1 2.14 % $ 7.74 B usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 2.76 -8.35 % $ 36.8 M usaUSA
PolarityTE PolarityTE
PTE
- -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 9.01 -2.86 % $ 543 M usaUSA
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 54.13 2.46 % $ 151 M israelIsrael
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
- -23.43 % $ 495 K usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
Novan Novan
NOVN
- -24.84 % $ 2.64 M usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
- -48.37 % $ 3.71 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
- - $ 4.55 M irlandaIrlanda
Annovis Bio Annovis Bio
ANVS
$ 0.81 9.63 % $ 16.6 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
- - $ 218 M usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 3.02 -2.27 % $ 128 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.52 -0.62 % $ 5.75 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
- - $ 4.62 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
NanoString Technologies NanoString Technologies
NSTG
- -37.43 % $ 5.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.36 5.82 % $ 2.83 M israelIsrael
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 4.44 6.99 % $ 1.97 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
- -29.58 % $ 126 M usaUSA